Iradimed price to sales ratio IRMD

Market value divided by revenue over the last twelve months, since 2015.

Today, Oct 23, 2026: 12.7×
10-year median: 8.9×
Against its 10-year history: 86th; percentile: 0 is its lowest day, 100 its highest
10-year range: 2.5× to 16.4×
Peer median: 2.0×

Iradimed's price to sales ratio is 12.7× as of Oct 23, 2026.

That is above its ten-year median of 8.9×, higher than on 86% of days in the last ten years.

Over that time it ranged from 2.5× in Feb 2017 to 16.4× in Feb 2026.

The median for 10 medical instruments and supplies stocks of a similar size is 2.0×.

Price to sales ratio over time

median 8.9×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	12.7×	12.2×	16.4×
2025	15.4×	8.6×	15.4×
2024	9.7×	7.9×	10.0×
2023	9.5×	7.5×	11.3×
2022	7.1×	7.0×	15.9×
2021	14.8×	8.0×	14.8×
2020	8.2×	5.0×	9.0×
2019	7.9×	6.3×	10.7×
2018	8.8×	6.1×	14.8×
2017	7.1×	2.5×	7.1×
2016	3.4×	2.8×	10.3×
2015	11.8×	10.2×	16.0×

Against its peers

Companies in Medical - Instruments & Supplies nearest Iradimed's size, closest first, today.

Company	Price to sales ratio
IRMDIradimed	12.7×
STAAStaar Surgical	3.3×
BVSBioventus	2.2×
CDRECadre	1.9×
EYENational Vision	0.7×
MOVMovado	1.0×
LMATLemaitre Vascular	7.4×
INSPInspire Medical Systems	2.3×
MDXGMimedx	1.6×
TCMDTactile Systems Technology	1.5×
UFPTUFP Technologies	3.6×
Peer median	2.0×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Iradimed

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.